Table 4 Virucidal efficacy of formulated microbicidal actives tested per ASTM-E1052-20 Standard against HCoV-229E or SARS-CoV-2 in suspension inactivation studies.

From: Microbicidal actives with virucidal efficacy against SARS-CoV-2 and other beta- and alpha-coronaviruses and implications for future emerging coronaviruses and other enveloped viruses

Product type

Active ingredient concentration

Temperature (°C)

Contact time (min)

Organic load

Log10 reduction in infectious titer achieved

In product

Tested

Alpha-coronavirus

Beta-coronavirus

HCoV-229E

SARS-CoV-2

Bar soap

PCMX (0.090% w/w)

0.014% w/w (tested at 1:6.25 of supplied)

37 ± 1

0.5, 1a

5% FBS

 ≥ 3.3

 ≥ 4.1

Liquid gel handwash

Salicylic acid (0.10% w/w)

0.025% w/w (tested at 1:4 of supplied)

37 ± 1

0.5, 1a

5% FBS

 ≥ 3.6, ≥ 3.6,

 ≥ 3.6

Foaming handwash

Benzalkonium chloride (0.10% w/w)

0.025% w/w (tested at 1:4 of supplied)

37 ± 1

1

5% FBS

 ≥ 3.3, ≥ 3.3

 ≥ 3.4

Salicylic acid (0.09% w/w)

0.023% w/w (tested at 1:4 of supplied)

37 ± 1

0.5, 1a

5% FBS

 ≥ 3.5, ≥ 3.8

 ≥ 5.0

  1. Where multiple cvalues are shown, these represent different technical replicates.
  2. Abbreviations used: FBS, fetal bovine serum; HCoV-229E, human coronavirus strain 229E; PCMX, p-chloro-m-xylenol; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, w/w, weight-to-weight.
  3. aA 1-min contact time was used for testing against HCoV-229E; an 0.5-min contact time was used for testing against SARS-CoV-2.
Back to article page